CorMedix Inc. is a biopharmaceutical company based in New York, NY, dedicated to developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. Their focus lies in reducing and treating infectious and inflammatory diseases, with a particular emphasis on catheter-related bloodstream infections (CRBSIs) in hemodialysis patients.
Through their innovative research and development efforts, CorMedix has gained approval from the U.S. FDA for their product, DefenCath, which is designed to significantly reduce the incidence of CRBSIs in adult hemodialysis patients. With a strong commitment to improving patient outcomes, CorMedix continues to pursue therapeutic options that address critical medical needs.
Generated from the website